^
Association details:
| Biomarker: | MYC amplification |
|---|---|
| Cancer: | Esophageal Cancer |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma
Excerpt:
...- c-MYC or HER2 gene amplification as defined in trial protocol...
Trial ID:
Source:
Title:
The iMYC study to assess the effectiveness and safety of ibrutinib in patients with advanced oesophagogastric cancer with c-MYC and HER2 gene amplification
Excerpt:
...For HER2 positive tumours documented progression after at least 1 line of chemotherapy with or without HER2 directed therapy.-c-MYC or HER2 gene amplification as defined in trial protocol-Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study. ...
Trial ID:
Less C2 evidence
Source:
Title:
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer
Published date:
08/22/2017
Excerpt:
Consistent with this, our analysis of ibrutinib sensitivity in oesophageal tumour cell lines revealed that there was preferential sensitivity to ibrutinib in both MYC amplified and/or ERBB2 amplified oesophageal tumour cell lines (p=0.018, Mann-Whitney U test, figure 5A,B).
DOI:
10.1136/gutjnl-2017-314408
